Peter Lynch fit · Growth at a reasonable price (GARP)
Is Alnylam Pharmaceuticals, Inc. (ALNY) a Peter Lynch Stock?
Strong GARP candidate - growth at a reasonable price.
75/100
BLikely Lynch stock
3/6 criteria passed
Peter Lynch's Criteria, Applied to ALNY
PEG ≤ 1.0
key-
EPS CAGR ≥ 15%
key-
Revenue CAGR ≥ 10%
44.8%
Net margin > 0
13.5%
Manageable debt (D/E < 1)
1.2x
Positive free cash flow
Yes
How ALNY Scores on Other Strategies
Live Financial Snapshot
Market cap
$40.32B
P/E (TTM)
68.1x
ROIC (TTM)
19.66%
Gross margin
80.89%
Other Peter Lynch fit reports
Frequently Asked Questions
What is ALNY's Peter Lynch fit score?
ALNY scores 75/100 on our Peter Lynch fit engine - grade B. Strong GARP candidate - growth at a reasonable price.
Does Peter Lynch actually own ALNY?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends ALNY.
How often is this score updated?
ALNY's Peter Lynch fit score is recomputed daily from the latest TTM financials. The page below shows when it was last refreshed.
Key terms in this analysis
Educational tool, not investment advice. Scores are computed from publicly-available financial data against published investing-strategy criteria. We do not claim that Peter Lynch personally owns or recommends ALNY.